1316758-27-6

1316758-27-6 structure

Name: Brimonidine-D4 D-Tartrate
Chemical Name: Brimonidine-D4 D-Tartrate
CAS Number: 1316758-27-6
Molecular Formula: C₁₅H₁₆BrN₅O₆
Molecular Weight: 442.22144
Catalog: Signaling Pathways GPCR/G Protein Adrenergic Receptor
Create Date: 2018-07-01 02:48:15
Modify Date: 2024-01-12 19:08:29
Brimonidine-d4 (UK 14304-d4) D-tartrate is the deuterium labeled Brimonidine D-tartrate[1].

Name	Brimonidine-D4 D-Tartrate

Description	Brimonidine-d4 (UK 14304-d4) D-tartrate is the deuterium labeled Brimonidine D-tartrate[1].
Related Catalog	Research Areas >> Endocrinology Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Andorn, A.C., M.A. Carlson, and R.C. Gilkeson, Specific [3H]UK 14,304 binding in human cortex occurs at multiple high affinity states with alpha 2-adrenergic selectivity and differing affinities for GTP. Life Sci, 1988. 43(22): p. 1805-12. [3]. Cambridge, D., UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol, 1981. 72(4): p. 413-5. [4]. Chopin, P., F.C. Colpaert, and M. Marien, Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther, 1999. 288(2): p. 798-804.